TPI

Tianyin Pharmaceutical Co., Inc. Launches Advertising Program on China Central Television (CCTV) for its Xuelian Chongcao Oral Liquid

... CHENGDU, China, June 29 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE AMEX: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has engaged a major...

Tianyin Pharmaceutical Co., Inc. Set to Join Russell Microcap(R) Index

... CHENGDU, China, June 22 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE AMEX: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it is set to join the ...

Tianyin Pharmaceutical Co., Inc. Provides Fiscal 2010 Guidance

... net income, representing approximately 40% and 42% growth over estimated fiscal 2009. Tianyin Pharmaceutical, Co., Inc., (NYSE AMEX: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced its unaudited, preliminary ...

Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Third Quarter Earnings Conference Call on Friday, May 15, 2009 at 11:00 a.m. EDT

... CHENGDU, China, May 11 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that management will hold a...

Tianyin Pharmaceutical Co. Inc.'s Ginkgo Mihuan Oral Solution Completes 2009 Tenders

... CHENGDU, China, April 21 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that it has completed the n...

Tianyin Pharmaceutical Co., Inc. Series A Preferred Shareholders Approved Cash Dividend to Common Stockholders

... CHENGDU, China, April 14 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that its Series A Preferred...

Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders

... CHENGDU, China, March 26 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Board of Directors...

Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 First Quarter Earnings Conference Call on Tuesday, November 11, 2008 at 8:30 a.m. EST

... CHENGDU, China, Nov. 6 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that management will hold a...

Tianyin Pharmaceutical Co., Inc. Authorizes $3.0 Million Stock Repurchase Program

... CHENGDU, China, Oct. 28 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company's board of...

Eric Rowinsky, M.D. and Martin Cannon Join Tapestry Board of Directors

...icals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, tpi 287 is in multiple Phase 2 clinical studies at this time. For more information about Tapestry and its technologies, visit Tapestry's website at htt...

TPI in Medical Technology

NicOx Announces TOPIGEN Initiates Phase 2 Proof of Concept Study in COPD for TPI 1020

SOPHIA ANTIPOLIS, France, Nov. 20 /PRNewswire/ -- NicOx S.A. (Eurolist: COX) today announced that TOPIGEN Pharmaceuticals Inc. has dosed the first patients in a phase 2 proof of concept study for TPI 1020 in Chronic Obstructive Pulmonary Disease (COPD) - see TOPIGEN press release attached. Thi...

Tapestry Announces Strategy to Focus on TPI 287 Clinical Program

Company downsizing non-clinical workforce BOULDER, Colo., Oct. 26 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH ), announced today a plan to focus all of its resources on advancing TPI 287's on-going and previously announced clinical trials. As part of ...

Tapestry Pharmaceuticals Presents Data on TPI 287 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

BOULDER, Colo., Oct. 23 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH ), is presenting data today at the AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. This year's conference is being held October 22-26, 2007 at the Moscone Conv...

Tapestry Initiates Phase 2 Trial of TPI 287 for the Treatment of Advanced Pancreatic Cancer

BOULDER, Colo., Oct. 3 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. (Nasdaq: TPPH ) announced today that it has initiated a Phase 2 open- label, multi-center study of TPI 287 in patients with advanced pancreatic cancer. This is the second Phase 2 trial exploring the activity of TP...

Tapestry Pharmaceuticals to Present Data on TPI 287 at the 2007 AACR Annual Meeting

BOULDER, Colo., March 14, 2007 /PRNewswire-FirstCall/ -- Tapestry Pharmaceuticals, Inc. today announced that it will present new data at the 2007 American Association for Cancer Research (AACR) Annual Meeting, April 14-18 in Los Angeles, Calif. Scientists from Tapestry Pharmaceuticals will discuss...

Financial Results for Full Year 2007: NicOx Significantly Advances Clinical Programs

...Initiation of a phase 2 proof-of-concept study for tpi 1020 in Chronic Obstructive Pulmonary Disease ...10.0 million in payments from Merck during 2007. tpi 1020 advanced into a phase 2 proof-of-concept stud...t patients in a phase 2 proof-of-concept study for tpi 1020 (formerly NCX 1020) in Chronic Obstructive Pu...

NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results

... of reference. TOPIGEN Pharmaceuticals to Advance tpi 1020 Into Phase 2 Development for COPD Phase 2a S...cessful completion of a Phase 2a safety trial with tpi 1020 in smokers with asthma. TOPIGEN also announc...lmonary disease (COPD) in the second half of 2007. tpi 1020 is a novel anti-inflammatory respiratory drug...

Tapestry Reports Second Quarter 2007 Results

...ct Continued Investment in Clinical Development of tpi 287 BOULDER, Colo., Aug. 9 /PRNewswire-FirstCall...mpany, as we initiated our first Phase 2 trial for tpi 287, in hormone refractory prostate cancer, and sh...website at http://www.tapestrypharma.com . About tpi 287 ...

New Study Shows Doxorubicin Plus Paclitaxel Followed by Weekly Paclitaxel as Adjuvant Therapy for High Risk Breast Cancer Warranted in Place of Doxorubicin Plus Cyclophosphamide Followed by Paclitaxel

...tor of Managed Care, US Oncology: Assessment of medication safety in the outpatient setting -- Manuel Modiano, M.D.: A phase I study of tpi 287, a third generation taxane, administered every 21 days in patients with advanced cancer -- Joanne Blum, M.D., Ph.D.: Phase II study...

TPI in Biological Technology

Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders

... CHENGDU, China, July 8 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today declared a quarterly cash dividend to...

Financial Results for Full Year 2008: NicOx in a Unique Position to Deliver Significant Shareholder Value

...retinopathy. Results of a phase 2 study for tpi 1020 in COPD In December, NicOx and its par... Inc. announced the results of a phase 2 study for tpi 1020 in patients with Chronic Obstructive Pulmonary Disease (COPD). tpi 1020 did not obtain the differentiated activity re...

Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST

... CHENGDU, China, Feb. 11 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (NYSE: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that management will hold a...

Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results

...ved Chinese SFDA Approval for Fuke Zhidai Tablets CHENGDU, China, Nov. 11 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical Co., Inc., (NYSE: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced results for its first quart...

AMDL, Inc. Names Douglas MacLellan as Executive Chairman & CEO

...ctor of Edgewater Foods International Inc. (OTC Bulletin Board: EDWT), and Financial Advisor and Consultant to Tianyin Pharmaceutical Co, Inc. (Amex: tpi ) and JPAK Group Inc. (OTC Bulletin Board: JPAK). With TriPoint, Mr. Boswell has assisted numerous companies, providing high-level advice related corp...

Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST

... CHENGDU, China, Oct. 27 /Xinhua-PRNewswire-FirstCall/ -- Tianyin Pharmaceutical, Co., Inc., (Amex: tpi ), a manufacturer and supplier of modernized traditional Chinese medicine ("TCM") based in Chengdu, China, today announced that the Company will prese...

Tapestry Receives Nasdaq Delisting Notice

...icals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, tpi 287 is in multiple Phase 2 clinical studies funded by a development partner. For more information about Tapestry and its technologies, visit Tapestr...

Tapestry Receives Notice Regarding Minimum Bid Price Rule

...icals, Inc. is a biopharmaceutical company focused on the development of proprietary therapies for the treatment of cancer. Tapestry's lead candidate, tpi 287 is in multiple Phase 2 clinical studies at this time. For more information about Tapestry and its technologies, visit Tapestry's website at htt...

Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial

... 60% of second line HRPC patients on tpi 287 show clinical benefit BOULDER, Colo., Nov. 5...is currently actively enrolling. Phase 2 Trial of tpi 287 for Pancreatic Cancer Initiated Tapestry also... a second Phase 2 trial to explore the activity of tpi 287 in advanced pancreatic cancer. The trial is a ...